The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Event
  • Marketing

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Proper Sky Named to the 2026 MSP 501
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • The Lashe Announces Limited-Time Sale on Professional Premade Fan Lash Extension Trays
  • PropAccount.com Adds Prediction Markets to Its Multi-Asset Prop Firm Platform
  • ToyLookup.com Launches AI-Powered Platform to Help Collectors Identify Vintage and Modern Toys
  • Rising star Hip-Hop and R&B Force Della Drops Highly Anticipated New Single, "Throw It"
  • UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • Fig Lehigh Valley Celebrates 50th Edition With Summer Launch Party at the Americus Hotel
  • Make America French Again Launches National Campaign
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • New Children's Book Teaches Kids the Lesson Its Author Spent a Career Learning: Your Worth Doesn't Need Permission
  • Proper Sky Named to the 2026 MSP 501
  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
  • Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
  • Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
  • Webinar Announcement: Built for Trust: Latitude's 0 to 1 Compliance Playbook for Modern Cross-Border Payments
  • OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
  • Dentists launch independent platform to help practices choose the right technology
  • Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
  • Former MP Shri GV Harsha Kumar Meets AICC President Mallikarjun Kharge
  • Two Attorneys at The Stanley Law Group Named to 2026 South Carolina Super Lawyers List
  • IGH Naturals Announces Peer-Reviewed HuMOLYTE® Study Published in Frontiers in Nutrition
  • LINC to Host CEO Breakfast Forum on July 22

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 268
  • Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
  • $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Wine School of Philadelphia Celebrates 25 Years With Intensive Summer Program
  • New Luxury Single Family Homes From $976,990 in Manalapan
  • Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
  • What Would you Do with Your Time if it Was Actually Money?
  • Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision

Similar on PennZone

  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us